What is the price target for NGNE stock?
14 analysts have analysed NGNE and the average price target is 79.22 USD. This implies a price increase of 185.58% is expected in the next year compared to the current price of 27.74.
NEUROGENE INC (NGNE) Forecast, Price Target & Analyst Ratings
NASDAQ:NGNE • US64135M1053
Current stock price
27.74 USD
-0.11 (-0.39%)
At close:
27.74 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUROGENE INC (NGNE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 8, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.33
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$79.22
Upside
+ 185.58%
From current price of $27.74 to mean target of $79.22, Based on 14 analyst forecasts
Low
$46.46
Median
$61.20
High
$189.00
Price Target Revisions
1 Month
31.64%
3 Months
31.64%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for NGNE. The average price target is 79.22 USD. This implies a price increase of 185.58% is expected in the next year compared to the current price of 27.74.
The average price target has been revised upward by 31.64% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
NGNE was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about NGNE.
In the previous month the buy percentage consensus was at a similar level.
NGNE was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-27 | Canaccord Genuity | Initiate | Buy |
| 2026-01-26 | LifeSci Capital | Initiate | Outperform |
| 2026-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-17 | Craig-Hallum | Initiate | Buy |
| 2025-06-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-05-20 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-05-16 | Baird | Downgrade | Outperform -> Neutral |
| 2025-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-14 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-20 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-11-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-11-12 | Stifel | Maintains | Buy -> Buy |
| 2024-11-12 | Baird | Maintains | Outperform -> Outperform |
| 2024-11-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-27 | BMO Capital | Initiate | Outperform |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 8, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.33
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -23.18%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-1.63%
EPS (3 Months)
-6.47%
Next Earnings Summary
NGNE is expected to report earnings on 5/8/2026. The consensus EPS estimate for the next earnings is -1.33 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 925K | -100.00% | 25.262M | 335.25M 1,227.09% | 674.65M 101.24% | 1.041B 54.30% | 1.027B -1.34% | 1.003B -2.34% | |||||
| EBITDA YoY % growth | -57.536M 3.13% | -52.321M 9.06% | -79.31M -51.58% | N/A -26.32% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -59.097M 2.64% | -55.583M 5.95% | -82.505M -48.44% | -104.888M -25.12% | -127.111M -23.14% | -138.116M -8.66% | -116.471M 15.67% | 147.5M 226.64% | 495.67M 236.05% | 737.36M 48.76% | 827.07M 12.17% | 548.76M -33.65% | |
| Operating Margin | N/A | N/A | -8,919.46% | N/A | N/A | N/A | -461.05% | 44.00% | 73.47% | 70.83% | 80.53% | 54.71% | |
| EPS YoY % growth | -20.80 5.04% | N/A 72.65% | -4.27 24.93% | -4.35 -0.47% | -5.24 -22.06% | -5.90 -12.64% | -6.77 -14.74% | 7.21 206.48% | 16.88 134.18% | 15.09 -10.61% | 15.28 1.28% | 12.10 -20.83% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.33 -23.18% | -1.33 -26.29% | -1.32 -32.91% | -1.34 -14.35% | -1.33 0.33% | -1.40 -5.38% | -1.45 -10.08% | -1.51 -12.83% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -27.961M -22.20% | -28.592M -9.63% | -29.389M -23.49% | -30.524M -11.28% | -30.6M -9.44% | -32.13M -12.37% | -33.15M -12.80% | -34.17M -11.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-16.41%
EPS Next 5 Year
42.78%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NEUROGENE INC / NGNE Forecast FAQ
What is the next earnings date for NGNE stock?
NEUROGENE INC (NGNE) will report earnings on 2026-05-08, before the market open.
What are the consensus estimates for NGNE stock next earnings?
The consensus EPS estimate for the next earnings of NEUROGENE INC (NGNE) is -1.33 USD and the consensus revenue estimate is 0 USD.
Can you provide the analyst count for NEUROGENE INC stock?
The number of analysts covering NEUROGENE INC (NGNE) is 14.